EUVIMEDObjevte EUVIMED
Crossref

Removal of empty capsids from high‐dose adeno‐associated virus 9 gene therapies

William S Kish, John Lightholder, Tamara Zeković, Alex Berrill, Matthew Roach, William B Wellborn, Eric Vorst

Biotechnology and Bioengineering · 2024-08 · 121 (8) · 2500-2523

DOI: 10.1002/bit.28737 ↗

At a glance

Journal article in Biotechnology and Bioengineering, published online on 2024-05-28. Written by William S Kish and 6 co-authors. Institution: Gene Therapy Process Development, Pfizer Inc., Morrisville, North Carolina, USA. Major MEDLINE topics: Dependovirus, Genetic Therapy, Capsid. Cited 11 times so far (Crossref); 77 references. Funded by: Pfizer Inc.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Recombinant adeno‐associated virus, serotype 9 (rAAV9) has shown promise as a gene therapy vector for muscle and central nervous diseases. High‐dose requirements of these therapies present critical safety considerations and biomanufacturing challenges. Notably, the reduction of empty capsids (ECs), which lack therapeutic transgene, from rAAV9 products is critical to maximize efficacy. Removal of rAAV ECs from full capsids is a major downstream challenge because of their highly similar biophysical characteristics. Ultracentrifugation (UC) reduces ECs but is laborious and difficult to scale. In this paper, to replace a poorly scalable UC process, we developed an anion exchange (AEX) chromatography for rAAV9 EC reduction from full capsids. AEX load preparation by dilution incurred major product loss. The addition of histidine and surfactants to dilution buffers increased yield and reduced aggregation. Elution salts were screened and sodium acetate was found to maximize yield and EC reduction. The most promising load dilution buffer and elution salt were used in combination to form an optimized AEX method. The process reduced ECs three‐fold, demonstrated robustness to a broad range of EC load challenges, and was scaled for large‐scale manufacture. Compared to UC, the AEX method simplified scale‐up, reduced ECs to comparable levels (20%), afforded similar purity and product quality, and increased yield by 14%.

Subjects

MeSH terms (MEDLINE)

DependovirusGenetic TherapyCapsidHumansGenetic VectorsChromatography, Ion ExchangeUltracentrifugation

Author keywords

adeno‐associated virusanion‐exchange chromatographyempty capsidshigh‐dose gene therapyscalabilityultracentrifugation

Authors and institutions

  • Gene Therapy Process Development, Pfizer Inc., Morrisville, North Carolina, USA.
  • Gene Therapy Process Development, Pfizer Inc., Chesterfield, Missouri, USA.

Funding

  • Pfizer Inc

Cite

APA

Kish, W. S., Lightholder, J., Zeković, T., Berrill, A., Roach, M., Wellborn, W. B., & Vorst, E. (2024). Removal of empty capsids from high‐dose adeno‐associated virus 9 gene therapies. Biotechnology and Bioengineering, 121(8), 2500-2523. https://doi.org/10.1002/bit.28737

Vancouver

Kish WS, Lightholder J, Zeković T, Berrill A, Roach M, Wellborn WB, et al. Removal of empty capsids from high‐dose adeno‐associated virus 9 gene therapies. Biotechnology and Bioengineering. 2024;121(8):2500-2523. doi:10.1002/bit.28737

BibTeX
@article{Kish2024,
  author = {Kish, William S and Lightholder, John and Zeković, Tamara and Berrill, Alex and Roach, Matthew and Wellborn, William B and Vorst, Eric},
  title = {Removal of empty capsids from high‐dose adeno‐associated virus 9 gene therapies},
  journal = {Biotechnology and Bioengineering},
  year = {2024},
  volume = {121},
  number = {8},
  pages = {2500--2523},
  doi = {10.1002/bit.28737}
}
Start for free →